Frequency falters after phase 2 fail, axing 2 assets and 55% of staff – FierceBiotech

by

  1. Frequency falters after phase 2 fail, axing 2 assets and 55% of staff FierceBiotech
  2. Lexington biotech lays off half of its workforce after hearing loss drug fails major study The Boston Globe
  3. Biotech layoffs 2023: Frequency Therapeutics to lay off most of its staff in wake of trial failure – Boston Business Journal The Business Journals
  4. Frequency stock crashes 75% on cutting hearing loss programs as trial fails; cuts 55% jobs Seeking Alpha
  5. Frequency Therapeutics President, CEO Lucchino Takes Medical Leave >FREQ MarketWatch
  6. View Full Coverage on Google News

Read original article here

Leave a Comment